|
1
|
Kröger N, Achterrath W, Hegewisch-Becker
S, Mross K and Zander AR: Current options in treatment of
anthracycline-resistant breast cancer. Cancer Treat Rev.
25:279–291. 1999.PubMed/NCBI
|
|
2
|
Cai X, Bikadi Z, Ni Z, et al: Role of
basic residues within or near the predicted transmembrane helix 2
of the human breast cancer resistance protein in drug transport. J
Pharmacol Exp Ther. 333:670–681. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riordan JR and Ling V: Purification of
P-glycoprotein from plasma membrane vesicles of Chinese hamster
ovary cell mutants with reduced colchicine permeability. J Biol
Chem. 254:12701–12705. 1979.PubMed/NCBI
|
|
4
|
Cole SP, Bhardwaj G, Gerlach JH, Mackie
JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and
Deeley RG: Overexpression of a transporter gene in a
multidrug-resistant human lung cancer cell line. Science.
258:1650–1654. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Noguchi K, Katayama K, Mitsuhashi J and
Sugimoto Y: Functions of the breast cancer resistance protein
(BCRP/ABCG2) in chemotherapy. Adv Drug Deliv Rev. 61:26–33. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Allikmets R, Schriml LM, Hutchinson A,
Romano-Spica V and Dean M: A human placenta-specific ATP-binding
cassette gene (ABCP) on chromosome 4q22 that is involved in
multidrug resistance. Cancer Res. 58:5337–5339. 1998.PubMed/NCBI
|
|
8
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 83:1084–1103. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yuan J, Lv H, Peng B, Wang C, Yu Y and He
Z: Role of BCRP as a biomarker for predicting resistance to
5-fluorouracil in breast cancer. Cancer Chemother Pharmacol.
63:1103–1110. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lagas JS, van Waterschoot RA, van Tilburg
VA, et al: Brain accumulation of dasatinib is restricted by
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)
and can be enhanced by elacridar treatment. Clin Cancer Res.
15:2344–2351. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ni Z, Bikadi Z, Rosenberg MF and Mao Q:
Structure and function of the human breast cancer resistance
protein (BCRP/ABCG2). Curr Drug Metab. 11:603–617. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Polli JW, Olson KL, Chism JP, et al: An
unexpected synergist role of P-glycoprotein and breast cancer
resistance protein on the central nervous system penetration of the
tyrosine kinase inhibitor lapatinib
(N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine;
GW572016). Drug Metab Dispos. 37:439–442. 2009.PubMed/NCBI
|
|
13
|
Bates SE, Robey R, Miyake K, Rao K, Ross
DD and Litman T: The role of half-transporters in multidrug
resistance. J Bioenerg Biomembr. 33:503–511. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yuan JH, Zhou JM, Ji N, et al: Epigenetic
regulation mechanism of ABCG2 induced drug-resistant phenotype. J
Med Coll PLA. 26:243–253. 2011. View Article : Google Scholar
|
|
15
|
Zhang W, Ding W, Chen Y, et al:
Up-regulation of breast cancer resistance protein plays a role in
HER2-mediated chemoresistance through PI3K/Akt and nuclear
factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta
Biochim Biophys Sin (Shanghai). 43:647–653. 2011. View Article : Google Scholar
|
|
16
|
Yuan JH, He ZM, Yu YH and Chen ZC:
Expression establishment and functional analysis of breast cancer
resistance protein with doxycycline induced Tet regulating system
in mouse fibroblast cell line PA317. Chin J Cancer. 23:1127–1133.
2004.(In Chinese).
|
|
17
|
Yuan JH, He ZM, Lu H, et al: Breast cancer
resistance protein-mediated 5-fluorouracil resistance and its
mechanism. Chin J Pharmacol Toxicol. 19:357–362. 2005.
|
|
18
|
He ZM, Wei LY and Peng X: Assay of
sensitivity of cancer cell to anticancer drug in glass capillaries.
Chin J Cancer Res. 4:40–45. 1992. View Article : Google Scholar
|
|
19
|
Lemos C, Kathmann I, Giovannetti E, et al:
Cellular folate status modulates the expression of BCRP and MRP
multidrug transporters in cancer cell lines from different origins.
Mol Cancer Ther. 8:655–664. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kanzaki A, Toi M, Nakayama K, Bando H,
Mutoh M and Uchida T: Expression of multidrug resistance-related
transporters in human breast carcinoma. Jpn J Cancer Res.
92:452–458. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zheng G, Peng F, Ding R, Yu Y, et al:
Identification of proteins responsible for the multiple drug
resistance in 5-fluorouracil-induced breast cancer cell using
proteomics analysis. J Cancer Res Clin Oncol. 136:1477–1488. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
He Z, Yuan J, Chen Z, Liu S, Shen Z and
Fei H: Chemosensitivity test for 170 human breast carcinoma
samples. Hunan Yi Ke Da Xue Xue Bao. 23:531–534. 1998.(In
Chinese).
|
|
23
|
Volk EL, Farley KM, Wu Y, Li F, Robey RW
and Schneider E: Overexpression of wild-type breast cancer
resistance protein mediates methotrexate resistance. Cancer Res.
62:5035–5040. 2002.PubMed/NCBI
|
